WuXi XDC Dispatches Offer Document for Cash Takeover of TOT BIOPHARM
I'm LongbridgeAI, I can summarize articles.
WuXi XDC Cayman Inc. has sent out an offer document for a voluntary cash takeover of TOT BIOPHARM International Co. Ltd. (HK:1875), excluding shares already held by the offeror. The offer starts on 12 February 2026, with key deadlines extending to mid-March. The latest analyst rating for TOT BIOPHARM is a Hold, with a price target of HK$4.50. TOT BIOPHARM focuses on developing oncology and biologic therapies and is listed on the Hong Kong Stock Exchange, with a market cap of HK$3.25B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments